Page last updated: 2024-12-05

perillyl alcohol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(S)-(-)-perillyl alcohol : A perillyl alcohol in which the chiral centre has S configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

perillyl alcohol: inhibits geranylgeranyl transferase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

perillyl alcohol : A limonene monoterpenoid consists of a cyclohexene ring substituted by a hydroxymethyl and a prop-1-en-2-yl group at positions 1 and 4 respectively. It is a constituent of a variety of essential oils including lavender. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID369312
CHEMBL ID236687
CHEBI ID10782
SCHEMBL ID569985
MeSH IDM0100630
PubMed CID10819
CHEMBL ID444711
CHEBI ID15420
SCHEMBL ID296111
MeSH IDM0100630

Synonyms (137)

Synonym
MLS002695966
smr001562123
CHEBI:10782 ,
(4s)-perillyl alcohol
NCI60_013758
nsc641066
(s)-(-)-perillyl alcohol
nsc-641066
1-cyclohexene-1-methanol, 4-(1-methylethenyl)
18457-55-1
C02452
[(4s)-4-(prop-1-en-2-yl)cyclohex-1-en-1-yl]methanol
(-)-perillyl alcohol
(-)-perillylalcohol
(s)-perillyl alcohol
(s)-(-)-perillyl alcohol, >=95%, fg
(s)-(-)-perillyl alcohol, 96%
(-)-p-mentha-1,8-dien-7-ol
perilla alcohol, (s)-isomer
neo100
1-cyclohexene-1-methanol, 4-(1-methylethenyl)-, (4s)-
LMPR0102090008
perycorolle
neo-100
(-)-perilla alcohol
CHEMBL236687
(s)-p-mentha-1,8-dien-7-ol
(s)-4-isopropenyl-1-cyclohexenylmethanol
BMSE000559
(s)-(-)-(4-isopropenyl-1-cyclohexenyl)methanol
[(4s)-4-prop-1-en-2-ylcyclohexen-1-yl]methanol
SCHEMBL569985
(4-isopropenyl-1-cyclohexen-1-yl)methanol #
Q-201271
l-(-)-perillyl alcohol
unii-3ul4qiy642
3ul4qiy642 ,
(s)-(4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methanol
J-523912
perllyl alcohol,(reagent / standard grade)
(-)-perillyl alcohol, analytical standard
J-011826
A880768
(s)-(4-(prop-1-en-2-yl)cyclohex-1-enyl)methanol
(s)-(?)-perillyl alcohol
HY-116514
F16807
DB15289
Q27108674
perillyl-alcohol
(s)-(?)-perillyl alcohol?
CS-0065677
(s)-p-mentha-1,8-dien-7-ol, (s)-4-isopropenyl-1-cyclohexenylmethanol
AKOS016843795
AS-57413
(s)-()-perillyl alcohol
EN300-7353047
Z1255486314
unii-319r5c7293
ccris 8461
319r5c7293 ,
dihydrocuminyl alcoholn
[4-(prop-1-en-2-yl)cyclohex-1-en-1-yl]methanol
CHEBI:15420 ,
4-isopropenylcyclohex-1-en-1-ylmethanol
perillol
isocarveol
4-(1-methylethenyl)-1-cyclohexene-1-methanol
4-isopropenyl-1-cyclohexene carbinol
536-59-4
1-perillalcohol
1-hydroxymethyl-4-isopropenyl-1-cyclohexene
1-cyclohexene-1-methanol, 4-(1-methylethenyl)-
dihydrocuminic alcohol
para-mentha-1,8-dien-7-ol
SDCCGMLS-0066882.P001
iso-carveol
hydrocumin alcohol
cyclohex-1-ene-1-methanol, 4-(1-methylethenyl)-
nsc 641066
4-isopropenyl-cyclohex-1-ene-1-methanol
fema no. 2664
einecs 208-639-9
perilla alcohol
perillic alcohol
BSPBIO_003574
p-mentha-1,8-dien-7-ol
perillyl alcohol
NCGC00095297-02
NCGC00095297-01
KBIO3_002951
SPECTRUM3_001974
SPECTRUM2_000838
SPBIO_000795
SPECTRUM1505297
NCGC00095297-03
dihydrocuminyl alcohol
F9405E33-6136-4D27-A15E-C10CDC8C9AC4
dl-perillyl alcohol
(4-prop-1-en-2-ylcyclohexen-1-yl)methanol
FT-0690515
CHEMBL444711 ,
AKOS006227854
S3853
CCG-40267
FT-0627990
(+/-)-perillyl alcohol
(+/-)-1-cyclohexene-1-methanol, 4-(1-methylethenyl)-
perillyl alcohol [inci]
p-mentha-1,8-dien-7-ol [fhfi]
SCHEMBL296111
4-isopropenyl-cyclohex-1-enylmethanol
(4-isopropenyl-1-cyclohexen-1-yl)methanol
4-isopropenyl-1-cyclohexene-methanol
1,8-p-menthadien-7-ol
DTXSID4052180
(4-(prop-1-en-2-yl)cyclohex-1-en-1-yl)methanol
(4-(prop-1-en-2-yl)cyclohex-1-enyl)methanol
AC-35110
mfcd00062995
mfcd00001567
perill alcohol
sr-05000002384
SR-05000002384-1
A870664
bdbm50252404
Q15391928
bencynoatehydrochloride
stercobilinhydrochloride
BRD-A13323580-001-03-0
EN300-97783
CS-W019441
HY-N7000
SB45076
SY110506
(s)-[4-(1-propen-2-yl)-1-cyclohexen-1-yl]methanol
Z1198147170

Research Excerpts

Overview

Perillyl alcohol (POH) is a monocyclic terpene that has strong antitumor activity. It is an isoprenoid which inhibits farnesyl transferase and geranylgeranyl transferase, key enzymes that induce conformational and functional changes in small G proteins.

ExcerptReferenceRelevance
"Perillyl alcohol (POH) is a monoterpene which can be extracted from widely available essential oils and is known for its strong anti-inflammatory and anti-oxidant properties."( Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways: A comprehensive study onin-vitro and in-vivo experimental models.
Abubakar, M; Chamundeswari, D; Chaudhary, A; Gangasani, JK; Jain, S; Naidu, VGM; Np, S; Puppala, ER; Rachamalla, M; Saha, P; Usn, M; Yalamarthi, SS, 2022
)
2.89
"Perillyl alcohol (POH) is a monoterpene with antitumor activity that currently is undergoing clinical evaluation as an inhalational anticancer agent."( Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats.
Boaventura, GT; Chen, TC; Cho, HY; Da Fonseca, CO; de Lima, DC; Rodrigues, SV; Schönthal, AH, 2020
)
1.57
"Perillyl alcohol (POH) is a monocyclic terpene that has strong antitumor activity. "( Intranasal administration of perillyl alcohol-loaded nanoemulsion and pharmacokinetic study of its metabolite perillic acid in plasma and brain of rats using ultra-performance liquid chromatography/tandem mass spectrometry.
da Fonseca, CO; da Silva Santos, J; Diedrich, C; Khalil, NM; Machado, CS; Mainardes, RM, 2021
)
2.36
"Perillyl alcohol (POH) is an isoprenoid which inhibits farnesyl transferase and geranylgeranyl transferase, key enzymes that induce conformational and functional changes in small G proteins to conduct signal production for cell proliferation. "( Perillyl alcohol suppresses antigen-induced immune responses in the lung.
Dohi, M; Harada, H; Imamura, M; Kawahata, K; Nakagome, K; Okunishi, K; Sasaki, O; Tanaka, R; Yamamoto, K, 2014
)
3.29
"Perillyl alcohol (PA) is a monoterpene found in essential oils of mints, cherries, citreous fruits and lemon grass, reported to have antioxidant and anti-inflammatory properties. "( Perillyl alcohol improves functional and histological outcomes against ischemia-reperfusion injury by attenuation of oxidative stress and repression of COX-2, NOS-2 and NF-κB in middle cerebral artery occlusion rats.
Ahmed, ME; Ashafaq, M; Islam, F; Khan, A; Khan, MB; Safhi, MM; Shrivastava, P; Tabassum, R; Vaibhav, K, 2015
)
3.3
"Perillyl alcohol (POH) is a dietary monoterpene present in a variety of plants with a pure or mixed form, and it is one of the very few natural substances with anticancer activity. "( Perillyl alcohol efficiently scavenges activity of cellular ROS and inhibits the translational expression of hypoxia-inducible factor-1α via mTOR/4E-BP1 signaling pathways.
Jin, X; Lee, JJ; Li, J; Li, X; Ma, J; Mi, C; Piao, LX; Wang, KS; Xu, GH, 2016
)
3.32
"Perillyl alcohol (POH) is a naturally occurring monoterpene with antiangiogenic and anti-tumoral properties. "( Anti-thrombin as a prognostic biomarker candidate for patients with recurrent glioblastoma multiform under treatment with perillyl alcohol.
Carvalho, Mda G; Carvalho, PC; da Fonseca, CO; Domont, GB; Fischer, Jde S; Neves-Ferreira, AG; Perales, J, 2008
)
2
"Perillyl alcohol (POH) is a naturally occurring terpene and a promising chemotherapeutic agent for glioblastoma multiform; yet, little is known about its molecular effects. "( Dynamic proteomic overview of glioblastoma cells (A172) exposed to perillyl alcohol.
Barbosa, VC; Carvalho, Mda G; Carvalho, PC; Domont, GB; Fischer, Jde S; Liao, L; Yates, JR, 2010
)
2.04
"Perillyl alcohol (POH) is a monoterpene that has been used orally for the treatment of systemic cancer. "( Perillyl alcohol for the treatment of temozolomide-resistant gliomas.
Chen, TC; Cho, HY; Goldkorn, A; Hofman, FM; Jhaveri, N; Lee, DJ; Leong, MN; Louie, SG; Petasis, NA; Schönthal, AH; Torres, S; Tseng, J; Wang, W; Xu, T, 2012
)
3.26
"Perillyl alcohol is a plant-derived lipid with preclinical antitumor activity. "( A phase I trial of perillyl alcohol in patients with advanced solid tumors.
Azzoli, CG; Kris, MG; Krug, LM; Miller, VA; Ng, KK; Riedel, ER; Spriggs, DR; Tong, WP, 2003
)
2.09
"Perillyl alcohol (POH) is a monoterpene found in lavender, spearmint, and cherries. "( Perillyl alcohol as a chemopreventive agent in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis.
Aziz, R; Carlton, PS; Frankel, W; Gupta, A; Liston, BW; Nines, R; Stoner, GD, 2003
)
3.2
"Perillyl alcohol (POH) is a naturally occurring monoterpene that has been shown to possess chemotherapeutic as well as chemopreventive activity in animal tumor models and is currently in Phase I and Phase II clinical trials."( Perillyl alcohol as a radio-/chemosensitizer in malignant glioma.
Howard, SP; Rajesh, D; Stenzel, RA, 2003
)
2.48
"Perillyl alcohol (POH) is a relatively non-toxic agent that has been shown to be a promising anticancer monoterpene in preclinical models. "( Development of a perillyl alcohol topical cream formulation.
Gupta, A; Myrdal, PB, 2004
)
2.11
"Perillyl alcohol is a hydroxylated monocyclic monoterpene. "( Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells.
Chung, BH; Lee, HY; Lee, JS; Young, CY, 2006
)
3.22
"Perillyl alcohol (POH) is a dietary monoterpene with potential applications in chemoprevention and chemotherapy. "( Polycyclic aromatic hydrocarbon-induced CYP1B1 activity is suppressed by perillyl alcohol in MCF-7 cells.
Chan, NL; Leung, HY; Leung, LK; Wang, H; Wang, Y, 2006
)
2.01
"Perillyl alcohol (POH) is a naturally occurring lipid with preclinical activity against mammary carcinomas. "( Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer.
Attia, S; Bailey, HH; Chappell, R; Fass, T; Hansen, R; Harris, L; Jumonville, A; Love, RR; Shapiro, GR; Stewart, JA; Tutsch, K, 2008
)
2.08
"Perillyl alcohol (POH) is a natural product derived from plants such as cherry and lavendin. "( Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer.
Alberts, DS; Blanchard, J; Bozzo, PD; Brooks, C; Dorr, RT; Einspahr, JG; Gupta, A; Levine, N; McKenzie, NE; Myrdal, PB; Ranger-Moore, J; Saboda, KL; Salasche, SJ; Stratton, SP; Warneke, JA, 2008
)
2.09
"Perillyl alcohol was found to be a potent inducer of the neuroblastoma-derived cell line Neuro-2A."( Induction of differentiation in neuro-2A cells by the monoterpene perillyl alcohol.
Gould, MN; Shi, W, 1995
)
1.25
"Perillyl alcohol is a natural product from cherries and other edible plants. "( Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer.
Burke, YD; Crowell, PL; Siar Ayoubi, A, 1996
)
2
"Perillyl alcohol is a naturally occurring monoterpene found in lavender, cherries, and mint."( Chemopreventive effect of perillyl alcohol on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced tumorigenesis in (C3H/HeJ X A/J)F1 mouse lung.
Crist, KA; Gao, F; Kelloff, GJ; Lantry, LE; Lubet, RA; Wang, Y; You, M; Zhang, Z, 1997
)
1.32
"Perillyl alcohol is a monoterpene isolated from the essential oils of lavendin, peppermint, spearmint, cherries, celery seeds, and several other plants. "( Perillyl alcohol: applications in oncology.
Belanger, JT, 1998
)
3.19
"Perillyl alcohol (POH) is a monoterpene with anticarcinogenic and antitumor activity in murine tumor models. "( Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Adams, A; Gallo, JM; Halberr, T; Hudes, GR; Langer, CJ; Litwin, S; McCauley, RA; Qian, M; Ranganathan, S; Szarka, CE; Weiner, LM; Yeslow, G, 2000
)
2.03

Effects

Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies. It inhibits the prenylation of Ras and other proteins in many cell types. Perillylalcohol has been extensively studied for the treatment of peripheral and primary brain tumors.

ExcerptReferenceRelevance
"Perillyl alcohol (POH) has been extensively studied for the treatment of peripheral and primary brain tumors. "( Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats.
Andrews, S; Gould, MN; Haag, JD; Howard, SP; Nehra, G; Rettig, J; Thorne, RG, 2021
)
2.32
"Perillyl alcohol (POH) has been shown to have both chemopreventative and chemotherapeutic activities in preclinical studies. "( A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Alberti, D; Arzoomanian, RZ; Bailey, HH; Feierabend, C; Hohl, RJ; Holstein, SA; Lewis, KA; Marnocha, R; Simon, K; Stewart, J; Tutsch, KD; Wilding, G, 2004
)
2.09
"Perillyl alcohol (POH) has been shown to inhibit the farnesylation of small G-proteins such as Ras."( Effects of perillyl alcohol and heat shock treatment in gene expression of human lung adenocarcinoma cell line A549.
Carvalho, Mda G; Carvalho, PC; da Mota e Silva, MS; Fischer, Jde S; Gattass, CR; Paschoal, EM, 2006
)
1.45
"Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies."( Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G, 2008
)
1.32
"Perillyl alcohol has shown chemotherapeutic activity in preclinical systems through enhancing apoptosis."( A pilot study of perillyl alcohol in pancreatic cancer.
Crowell, PL; Cummings, OW; Madura, JA; Matos, JM; Patrick, LJ; Schmidt, CM; Thomas, HJ; Wiebke, EA, 2008
)
1.41
"Perillyl alcohol has antitumor activity against rat mammary and liver cancer. "( Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol.
Ayoubi, AS; Burke, YD; Crowell, PL; McKinzie, JH; Stark, MJ, 1995
)
1.98
"Perillyl alcohol has antitumor activity toward pancreas and other cancers with low toxicity. "( Induction of the apoptosis-promoting protein Bak by perillyl alcohol in pancreatic ductal adenocarcinoma relative to untransformed ductal epithelial cells.
Burke, YA; Burke, YD; Crowell, PL; McKinzie, JH; Stayrook, KR, 1997
)
1.99
"Perillyl alcohol has chemotherapeutic activity against pancreas cancers that have a K-ras oncogene, and it inhibits the prenylation of Ras and other proteins in many cell types."( Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells.
Barbhaiya, LH; Crowell, PL; McKinzie, JH; Stayrook, KR,
)
1.86

Actions

Perillyl alcohol (POH) displays preventive and therapeutic activity against a wide variety of tumor models. It has been suggested that this might be associated with the ability of POH to interfere with Ras prenylation.

ExcerptReferenceRelevance
"Perillyl alcohol (POH) displays preventive and therapeutic activity against a wide variety of tumor models, and it has been suggested that this might be associated with the ability of POH to interfere with Ras prenylation. "( Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion.
Clark, SS; Filiault, D; Gould, M; Perman, S; Ren, Z; Yang, X; Zhong, L, 2003
)
2.07
"Perillyl alcohol was found to inhibit the incorporation of [14C]mevalonolactone into RhoA and Rab6 but not Ras protein."( Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells.
Elson, CE; Gould, MN; Ren, Z, 1997
)
1.24

Treatment

Perillyl alcohol treatment also rapidly elicited reductions of NF-kappaB DNA-binding activity and target gene induction, which was associated with an increase in apoptosis in these B-lymphoma cells. Perillylalcohol treated vein grafts showed a 22% reduction in overall mean intimal thickness but a 25% increase in overallmean medial thickness.

ExcerptReferenceRelevance
"Perillyl alcohol treatment also rapidly elicited reductions of NF-kappaB DNA-binding activity and target gene induction, which was associated with an increase in apoptosis in these B-lymphoma cells."( Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway.
Berchtold, CM; Chen, KS; Gould, MN; Miyamoto, S, 2005
)
2.49
"Perillyl alcohol treated vein grafts showed a 22% reduction in overall mean intimal thickness (54 +/- 4 microns vs 69 +/- 3 microns; P = 0.006) but a 25% increase in overall mean medial thickness (86 +/- 4 microns vs 61 +/- 3 microns)."( Oral monoterpene therapy (perillyl alcohol) reduces vein graft intimal hyperplasia.
Barber, L; Davies, MG; Fulton, GJ; Hagen, PO; Svendsen, E, 1997
)
1.32

Pharmacokinetics

ExcerptReferenceRelevance
" on a continuous four times a day basis to characterize the maximum tolerated dose, toxicities, pharmacokinetic profile, and antitumor activity."( Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.
Alberti, D; Arzoomanian, RZ; Bailey, HH; Binger, K; Feierabend, C; Gould, MN; Marnocha, R; Pomplun, M; Ripple, GH; Simon, K; Tutsch, KD; Wahamaki, A; Wilding, G, 2000
)
0.57
" Day 15 DHPA Cmax values ranged from a mean +/- SD of 22."( Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Adams, A; Gallo, JM; Halberr, T; Hudes, GR; Langer, CJ; Litwin, S; McCauley, RA; Qian, M; Ranganathan, S; Szarka, CE; Weiner, LM; Yeslow, G, 2000
)
0.59

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effects of monoterpene perilly alcohol (POH) alone or in combination with STI571 on the proliferation and apoptosis of the cell line K562 positive for Bcr/Abl were investigated."( Effects of POH in combination with STI571 on the proliferation and apoptosis of K562 cells.
Chen, Y; Hu, D, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Further study of POH continues with a more frequent dosing schedule."( Phase I clinical trial of perillyl alcohol administered daily.
Alberti, D; Arzoomanian, RZ; Bailey, HH; Feierabend, C; Gould, MN; Pomplun, M; Ripple, GH; Stewart, JA; Tutsch, KD; Wilding, G, 1998
)
0.6
" Preliminary human trials have not demonstrated tumor regression at a four times daily dosage schedule."( Perillyl alcohol: applications in oncology.
Belanger, JT, 1998
)
1.74
" three times daily is well tolerated on a 14-day on/14-day off dosing schedule."( Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patients with refractory solid malignancies.
Adams, A; Gallo, JM; Halberr, T; Hudes, GR; Langer, CJ; Litwin, S; McCauley, RA; Qian, M; Ranganathan, S; Szarka, CE; Weiner, LM; Yeslow, G, 2000
)
0.59
" In vitro, all compounds demonstrated growth inhibition at a dose-response manner; however, manumycin, gliotoxin, and DHEA demonstrated an initial increase in growth rate at lower doses."( Chemopreventive efficacy of promising farnesyltransferase inhibitors.
Crist, KA; Hara, M; Lantry, LE; Lubet, RA; Wang, Y; You, M; Zeeck, A; Zhang, Z, 2000
)
0.31
"In adults with advanced malignancies, an interrupted administration schedule of POH did not reveal significant advantages over continuous dosing schedules."( A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Alberti, D; Arzoomanian, RZ; Bailey, HH; Feierabend, C; Hohl, RJ; Holstein, SA; Lewis, KA; Marnocha, R; Simon, K; Stewart, J; Tutsch, KD; Wilding, G, 2004
)
0.65
" A dose-response comparison with perillyl alcohol and alpha-pinene, two of its components, revealed a higher efficacy of mastic oil, pointing to a beneficial collective interaction among its ingredients."( Protective effects of mastic oil from Pistacia lentiscus variation chia against experimental growth of lewis lung carcinoma.
Kolisis, FN; Loutrari, H; Magkouta, S; Papapetropoulos, A; Psallidas, I; Roussos, C; Stathopoulos, GT, 2009
)
0.63
" Radiographic improvement and reduction of corticosteroid dosage (36%) further associated with a delay towards progression."( Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.
Caetano, RO; da Fonseca, CO; Futuro, D; Lins, IR; Quirico-Santos, T; Simão, M, 2011
)
0.68
" The intranasal route of administration has been preferred for dosing POH in early-stage clinical trials associated with promising outcomes in primary brain cancer."( Intranasal administration of the chemotherapeutic perillyl alcohol results in selective delivery to the cerebrospinal fluid in rats.
Andrews, S; Gould, MN; Haag, JD; Howard, SP; Nehra, G; Rettig, J; Thorne, RG, 2021
)
0.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
volatile oil componentAny plant metabolite that is found naturally as a component of a volatile oil.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
perillyl alcoholA limonene monoterpenoid consists of a cyclohexene ring substituted by a hydroxymethyl and a prop-1-en-2-yl group at positions 1 and 4 respectively. It is a constituent of a variety of essential oils including lavender.
limonene monoterpenoid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
perillyl aldehyde biosynthesis37

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency23.77810.168316.404067.0158AID720504
gemininHomo sapiens (human)Potency1.71400.004611.374133.4983AID624296; AID624297
TAR DNA-binding protein 43Homo sapiens (human)Potency31.62281.778316.208135.4813AID652104
Chain A, Ferritin light chainEquus caballus (horse)Potency44.66845.623417.292931.6228AID485281
15-lipoxygenase, partialHomo sapiens (human)Potency12.58930.012610.691788.5700AID887
67.9K proteinVaccinia virusPotency5.01190.00018.4406100.0000AID720580
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1B1Homo sapiens (human)Ki2.00000.00300.97417.4600AID1453022
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (74)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID344008Antiproliferative activity against human PC3 cells assessed as reduction of cell viability at 400 uM after 72 hrs by WST-1 assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis of phosphatidylated-monoterpene alcohols catalyzed by phospholipase D and their antiproliferative effects on human cancer cells.
AID1187577Induction of 4E-BP1 phosphorylation at Ser65 in human A549 cells at 500 uM after 6 hrs by Western blotting analysis2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
The identification of perillyl alcohol glycosides with improved antiproliferative activity.
AID1187579Induction of 4E-BP1 phosphorylation at Thr70 in human A549 cells at 500 uM after 6 hrs by Western blotting analysis2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
The identification of perillyl alcohol glycosides with improved antiproliferative activity.
AID743959Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 634-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K(+)-ATPase and Ras oncogene activity in cancer cells.
AID654521Binding affinity to Me-5-DSA labelled 1,2-dimyristoyl-sn-glycero-3-phosphocholine bilayer containing assessed as change in membrane fluidity by electron paramagnetic resonance spectroscopy2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Influence of the active compounds of Perilla frutescens leaves on lipid membranes.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID302173Antifungal activity against Candida albicans ATCC 90028 after 24 hrs2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Modifications of the chemical structure of terpenes in antiplasmodial and antifungal drug research.
AID654523Binding affinity to 5-DSA labelled 1,2-dimyristoyl-sn-glycero-3-phosphocholine bilayer containing assessed as change in membrane fluidity by electron paramagnetic resonance spectroscopy2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Influence of the active compounds of Perilla frutescens leaves on lipid membranes.
AID344010Antiproliferative activity against human HL60 cells at 400 uM by WST-1 assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis of phosphatidylated-monoterpene alcohols catalyzed by phospholipase D and their antiproliferative effects on human cancer cells.
AID654518Binding affinity to 1,2-dimyristoyl-sn-glycero-3-phosphocholine bilayer assessed as decrease in main phase transition temperature at high concentration by differential scanning calorimetry (Rvb = 24.4 deg C)2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Influence of the active compounds of Perilla frutescens leaves on lipid membranes.
AID1187578Induction of 4E-BP1 phosphorylation at Thr70 in human A549 cells at 250 uM after 6 hrs by Western blotting analysis2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
The identification of perillyl alcohol glycosides with improved antiproliferative activity.
AID654522Binding affinity to Me-16-DSA labelled 1,2-dimyristoyl-sn-glycero-3-phosphocholine bilayer containing assessed as change in membrane fluidity by electron paramagnetic resonance spectroscopy2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Influence of the active compounds of Perilla frutescens leaves on lipid membranes.
AID1187580Inhibition of S6 ribosomal protein phosphorylation in human A549 cells at 250 to 500 uM after 6 hrs by Western blotting analysis2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
The identification of perillyl alcohol glycosides with improved antiproliferative activity.
AID1187576Induction of 4E-BP1 phosphorylation at Ser65 in human A549 cells at 250 uM after 6 hrs by Western blotting analysis2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
The identification of perillyl alcohol glycosides with improved antiproliferative activity.
AID743925Inhibition of RAS oncogene activity in human Hs683 cells at 2 mM after 5 to 29 mins by ELISA2013European journal of medicinal chemistry, May, Volume: 634-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K(+)-ATPase and Ras oncogene activity in cancer cells.
AID302172Antifungal activity against Candida albicans ATCC 90028 after 48 hrs2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Modifications of the chemical structure of terpenes in antiplasmodial and antifungal drug research.
AID302171Antiplasmodial activity after 48 hrs against chloroquine-resistant Plasmodium falciparum FcM29-Cameroon by [3H]hypoxanthine uptake2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Modifications of the chemical structure of terpenes in antiplasmodial and antifungal drug research.
AID743958Cytotoxicity against human A549 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 634-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K(+)-ATPase and Ras oncogene activity in cancer cells.
AID743954Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 634-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K(+)-ATPase and Ras oncogene activity in cancer cells.
AID743956Cytotoxicity against human U373 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 634-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K(+)-ATPase and Ras oncogene activity in cancer cells.
AID1187573Cytotoxicity against human PC3 cells after 48 hrs by alamar blue assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
The identification of perillyl alcohol glycosides with improved antiproliferative activity.
AID6545191,2-dimyristoyl-sn-glycero-3-phosphocholine bilayer-water partition coefficient, K of the compound at 300 uM by isothermal titration calorimetry at 35 deg C2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Influence of the active compounds of Perilla frutescens leaves on lipid membranes.
AID344009Antiproliferative activity against human HL60 cells by WST-1 assay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis of phosphatidylated-monoterpene alcohols catalyzed by phospholipase D and their antiproliferative effects on human cancer cells.
AID344007Antiproliferative activity against human PC3 cells assessed as reduction of cell viability after 72 hrs by WST-1 assay relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis of phosphatidylated-monoterpene alcohols catalyzed by phospholipase D and their antiproliferative effects on human cancer cells.
AID654517Binding affinity to 1,2-dimyristoyl-sn-glycero-3-phosphocholine bilayer assessed as change in main phase transition temperature at low concentration by differential scanning calorimetry2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Influence of the active compounds of Perilla frutescens leaves on lipid membranes.
AID1187572Cytotoxicity against human A549 cells after 48 hrs by alamar blue assay2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
The identification of perillyl alcohol glycosides with improved antiproliferative activity.
AID1187575Induction of 4E-BP1 phosphorylation at Thr37/46 in human A549 cells at 500 uM after 6 hrs by Western blotting analysis2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
The identification of perillyl alcohol glycosides with improved antiproliferative activity.
AID743957Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 634-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K(+)-ATPase and Ras oncogene activity in cancer cells.
AID743955Cytotoxicity against human Hs683 cells after 72 hrs by MTT assay2013European journal of medicinal chemistry, May, Volume: 634-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K(+)-ATPase and Ras oncogene activity in cancer cells.
AID1187574Induction of 4E-BP1 phosphorylation at Thr37/46 in human A549 cells at 250 uM after 6 hrs by Western blotting analysis2014Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17
The identification of perillyl alcohol glycosides with improved antiproliferative activity.
AID654524Binding affinity to CSL labelled 1,2-dimyristoyl-sn-glycero-3-phosphocholine bilayer containing assessed as change in membrane fluidity by electron paramagnetic resonance spectroscopy2012Journal of natural products, Feb-24, Volume: 75, Issue:2
Influence of the active compounds of Perilla frutescens leaves on lipid membranes.
AID1453022Inhibition of recombinant human CYP1B1 expressed in supersomes using ethoxyresorufin as substrate after 20 mins in presence of NADPH by fluorescence assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (213)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.47)18.7374
1990's36 (16.90)18.2507
2000's72 (33.80)29.6817
2010's74 (34.74)24.3611
2020's30 (14.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.24 (24.57)
Research Supply Index5.45 (2.92)
Research Growth Index6.65 (4.65)
Search Engine Demand Index54.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials20 (9.43%)5.53%
Reviews0 (0.00%)6.00%
Reviews17 (8.02%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies2 (0.94%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
Other173 (81.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily In Patients With Metastatic Androgen Independent Prostate Cancer [NCT00003238]Phase 20 participants Interventional1998-02-28Completed
A PHASE I STUDY OF PERILLYL ALCOHOL IN PATIENTS WITH REFRACTORY MALIGNANCIES (NSC #641066) [NCT00002862]Phase 125 participants (Actual)Interventional1996-10-31Completed
An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation [NCT02704858]Phase 1/Phase 249 participants (Anticipated)Interventional2016-04-08Recruiting
Phase 2a Randomized, Placebo-Controlled, Double-Blind Trial of Topical Perillyl Alcohol in Sun Damaged Skin [NCT00608634]Phase 289 participants (Actual)Interventional2004-05-31Completed
Multiple-Dose Phase I and Pharmacokinetic Trial of Perillyl Alcohol [NCT00022425]Phase 10 participants Interventional2001-06-30Active, not recruiting
A Phase II Trial of Perillyl Alcohol in Patients With Resectable Pancreatic Cancer [NCT00003769]Phase 20 participants Interventional1999-02-28Completed
A Phase II Trial of Perillyl Alcohol (NSC 641066) Administered Daily in Patients With Metastatic Breast Cancer [NCT00003219]Phase 20 participants Interventional1998-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00608634 (2) [back to overview]Change in Histopathology Score of Sun Damaged Skin by Treatment Group
NCT00608634 (2) [back to overview]Skin Related Events From Perillyl Alcohol at Administered Doses by Participants

Change in Histopathology Score of Sun Damaged Skin by Treatment Group

The histopathologic scoring for skin biopsies from sun-damaged skin to assess the following seven characteristics: 1- atypia (levels 0, 1 & 2), 2- inflammation (grades 0, 1 & 2), 3- hyperkeratosis (loss of basket weave pattern of stratum corneum), 4- parakeratosis (present when there were >3 characteristic nuclei per 40:1 field in stratum corneum), 5- dyskeratosis (focal presence of cells with homogenous, pink cytoplasm n pyknotic nuclei), 6- epidermotropism (lymphocytes migration of >3 cells into epidermis, 7- loss of granular layer. All assessments were done using a 40:1 objective. (NCT00608634)
Timeframe: Baseline to 3 months

Interventionunits on a scale (Mean)
Placebo0.4
Low Dose POH 0.30%-0.1
High Dose POH 0.76%0.1

[back to top] [back to top]